Correlates with lung metastasis in chinese patients with osteosarcoma

Clinical and Investigative Medicine

Volumn 32, Issue 2, 2009, Pages

  Xu dong, Shen ^a   Zan, Shen ^a   Shui er, Zheng ^a   Li na, Tang ^a   Wen xi, Yu ^a   Feng, Lin ^a   Yang, Yao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EZRIN; FOLINIC ACID; HERMES ANTIGEN; IFOSFAMIDE; MESSENGER RNA; METHOTREXATE; TRANSCRIPTION FACTOR SIX1; CYTOSKELETON PROTEIN; HOMEODOMAIN PROTEIN; SIX1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHINESE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD44; CHILD; CYTOSKELETAL PROTEINS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 65249137692     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Théoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer. 2005;27:123.
2. McClatchey AI. Merlin and ERM proteins: Unappreciated roles in cancer development? Nat Rev Cancer 2003;3:877-83.
3. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/Ezrin complex in cancer metastasis [J]. Crit Rev Oncol Hematol. 2003;46:165-86.
4. Yu Y, Davicioni E, Triche TJ, et al. The Homeoprotein Six1 Transcriptionally Activates Multiple Protumorigenic Genes but Requires Ezrin toPromote Metastasis, Cancer Res. 2006;66:1982-9.
5. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-52.
6. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research, 2001;29:e45.
7. Rex C. Haydon, Lan Zhou, Tao Feng, et al. Nuclear Receptor Agonists As Potential Differentiation Therapy Agents for Human Osteosarcoma. Clinical Cancer Research 2002;8:1288-94.
8. Belgian society of fundamental and clinical physiology and pharmacologyabstracts of the winter meeting 2 march 2002, liege Fundamental & Clinical Pharmacology 2002;16:245-7
9. Caroline Laverdiere, Bang H. Hoang, RuiYang, et al. Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma. Clin Cancer Res. 2005;11:2561-6.
10. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586-99.
11. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol. Cell. 2000;92:305-16
12. McClatchey A.I. Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer 2003;3:877-83.
13. Gautreau A, Poullet P, Louvard D, et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1999;96:7300-5.
14. Crepaldi T, Gautreau A, Comoglio PM, et al. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol 1997;138:423-34.
15. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-25.
16. Takahashi K, Sasaki T, Mammoto A, et al. Direct interaction of the Rho GDP dissociation inhibitor with Ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem. 1997;272:23371-5.
17. Steeg, P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63.
18. Köbel M, Gradhand E, Zeng K, et al. Ezrin Promotes Ovarian Carcinoma Cell Invasion and Its Retained Expression Predicts Poor Prognosis in Ovarian Carcinoma. Int J Gynecol Pathol. 2006;25:121-30.
19. Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol. 2005;18:503-10.
20. Bal N, Yildirim S, Nursal TZ, et al. Association of Ezrin expression in intestinal and diffuse gastric carcinoma with clinicopathological parameters and tumor type, World J Gastroenterol. 2007;13:3726-9.
21. Weng WH, Ahlén J, Aström K, et al. Prognostic Impact of Immunohistochemical Expression of Ezrin in Highly Malignant Soft Tissue Sarcomas.Clin Cancer Res. 2005;11:6198-204.
22. Akisawa N, Nishimori I, Iwamura T, et al. High levels of Ezrin expressed by human pancreatic adenocarci- noma cell lines with high metastatic potential. Bio-chem Biophys Res Commun. 1999;258:395-400.
23. Zeng H, Xu L, Xiao D, et al. Altered Expression of Ezrin in Esophageal Squamous Cell Carcinoma. J His- tochem Cytochem. 2006;54:889-96.
24. Sarrió D, Rodríguez-Pinilla SM, Dotor A, et al. Abnormal Ezrin localization is associated with clinicopa- thological features in invasive breast carcinomas, Breast Cancer Res Treat. 2006;98:71-9.
25. Kim MS, Song WS, Cho WH, et al. Ezrin Expression Predicts Survival in Stage IIB Osteosarcomas. Clin Orthop Relat Res. 2007;459:229-36.
26. Park HR, Jung WW, Bacchini P, et al. Ezrin in osteo- sarcoma: Comparison between conventional high- grade and central low-grade osteosarcoma. Pathol Res Pract. 2006;202:509-15
27. Ferrari S, Zanella L, Alberghini M, et al. Prognostic Significance of Immunohistochemical Expression of Ezrin in Non-Metastatic High-Grade Osteosarcoma. Pediatric Blood Cancer 2008;50:752-6.
28. Laclef C, Hamard G, Demignon J, et al. Altered myo- genesis in Six1-deficient mice. Development 2003;130:2239-52
29. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer Ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81.